Lantheus Holdings Inc. (0L8)
Summary
0L8 Chart
US FDA declines to approve Lantheus' tumor imaging kit
The U.S. Food and Drug Administration declined to approve Lantheus Holdings' diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related conditions at a third-party facility, the company said on Friday.
Lantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lantheus weighs potential $7 billion sale, Bloomberg News reports
Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that could value it at about $7 billion, Bloomberg News reported on Friday, citing people familiar with the matter.
Lantheus Holdings Inc. (0L8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lantheus Holdings Inc. ever had a stock split?
Lantheus Holdings Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mary Anne Heino CEO | XETRA Exchange | US5165441032 ISIN |
| US Country | 1,193 Employees | - Last Dividend | - Last Split | 25 Jun 2015 IPO Date |
Overview
Lantheus Holdings, Inc., established in 1956 and headquartered in Bedford, Massachusetts, is a pioneering company in the medical diagnostics and therapeutics sector. The company is dedicated to developing, manufacturing, and marketing innovative diagnostic and therapeutic products that support clinicians in diagnosing and treating heart diseases, cancer, and other serious conditions globally. Lantheus distinguishes itself through its collaboration with prominent entities like GE Healthcare, NanoMab Technology Limited, Curium, RefleXion Medical, Inc., POINT, Regeneron Pharmaceuticals, Inc., and Ratio Therapeutics LLC, underscoring its commitment to advancing medical science and patient care.
Products and Services
Lantheus offers an extensive portfolio of products designed to enhance patient diagnosis and treatment across several disease states, including cardiovascular diseases, cancer, and more:
- DEFINITY: An injectable ultrasound enhancing agent used in echocardiography exams to improve the visualization of the heart.
- TechneLite: A technetium generator that is essential for various nuclear medicine procedures, aiding in the diagnosis and treatment of numerous conditions.
- Xenon-133: A radiopharmaceutical gas utilized to evaluate pulmonary function, providing critical insights into lung health.
- Neurolite: An injectable imaging agent that helps identify areas within the brain affected by stroke through the visualization of blood flow disruptions.
- Cardiolite: An injectable Tc-99m-labeled imaging agent used to assess myocardial blood flow and evaluate heart muscle health.
- PYLARIFY: An F 18-labelled PSMA-targeted PET imaging agent for detecting PSMA positive-lesions in men with prostate cancer, offering precision in diagnosis and treatment planning.
- Automated Bone Scan Index: A technology based on artificial intelligence that quantifies the burden of prostate cancer by classifying bone scan tracer uptakes, enhancing diagnostic accuracy.
- RELISTOR: A medication for the treatment of opioid-induced constipation, improving quality of life for patients on opioid therapy.
- aPROMISE: An artificial intelligence medical device software aimed at advancing the diagnosis and treatment of various diseases.
- PYLARIFY AI: An AI-based medical device software designed for the quantitative assessment of PSMA PET/CT images in prostate cancer, aiding in the precise quantification and characterization of disease.
- 1095: A PSMA-targeted iodine-131-labeled small molecule under development for advanced prostate cancer therapy.
- PNT2002: A radiopharmaceutical therapy being developed to treat metastatic castration-resistant prostate cancer, showcasing Lantheus' innovation in cancer treatment.
- PNT2003: An SSTR therapy for patients with SSTR-positive neuroendocrine tumors, reflecting Lantheus' commitment to addressing rare cancers.
- MK-6240: A F 18-labeled PET imaging agent targeting Tau tangles in Alzheimer's disease, instrumental in the advancement of neurodegenerative disease diagnosis.
- LNTH-1363S: A fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent, underlining Lantheus' dedication to novel diagnostic solutions.
- Flurpiridaz: An investigational agent used for assessing myocardial blood flow, further contributing to Lantheus' robust portfolio in cardiac care diagnostics.
